GlassScriptPhysician profile
Ryan M Baltes
NPI 1336634351
$3,867.66
in general payments reported to CMS, 2019-2025
30 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 88% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $672 · 2023: $1,006 · 2024: $964 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,032.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.73 | 2021-2025 | |
| Novo Nordisk INC | $550.94 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $381.40 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $272.77 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Xeris Pharmaceuticals, INC. | $232.50 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $183.23 | 2021-2025 | |
| Abbott Laboratories | $178.85 | 2024-2025 | Freestyle Libre 2 |
| Exact Sciences Corporation | $171.46 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $164.62 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.40 | 2021-2025 | Jardiance, Ofev |
| Amgen INC. | $125.64 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.89 | 2022-2025 | Xifaxan |
| Sanofi Pasteur INC. | $80.81 | 2022-2024 | |
| Pfizer INC. | $77.07 | 2023-2024 | |
| Dynavax Technologies Corporation | $56.79 | 2022-2023 | Heplisav-B |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $56.09 | 2022 | |
| Dexcom, INC. | $54.85 | 2022-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $50.55 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $49.61 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.09 | 2022-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Inspire Medical Systems, INC. | $45.32 | 2024-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $29.85 | 2021-2022 | |
| Glaxosmithkline, LLC. | $29.69 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Daiichi Sankyo INC. | $21.07 | 2025 | Injectafer |
| Shield Therapeutics INC | $18.10 | 2023 | Accrufer |
| Seqirus USA INC | $15.88 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Amarin Pharma, INC. | $14.25 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.08 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.59 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Baltes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.